JP2009533473A5 - - Google Patents

Download PDF

Info

Publication number
JP2009533473A5
JP2009533473A5 JP2009505615A JP2009505615A JP2009533473A5 JP 2009533473 A5 JP2009533473 A5 JP 2009533473A5 JP 2009505615 A JP2009505615 A JP 2009505615A JP 2009505615 A JP2009505615 A JP 2009505615A JP 2009533473 A5 JP2009533473 A5 JP 2009533473A5
Authority
JP
Japan
Prior art keywords
phenyl
pyrimidin
methoxy
ethylamino
dichloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2009505615A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009533473A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/066481 external-priority patent/WO2007121280A1/en
Publication of JP2009533473A publication Critical patent/JP2009533473A/ja
Publication of JP2009533473A5 publication Critical patent/JP2009533473A5/ja
Abandoned legal-status Critical Current

Links

JP2009505615A 2006-04-12 2007-04-12 プロスタグランジンd2受容体アンタゴニストとしての2,6−置換−4−モノ置換アミノ−ピリミジン Abandoned JP2009533473A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74467606P 2006-04-12 2006-04-12
PCT/US2007/066481 WO2007121280A1 (en) 2006-04-12 2007-04-12 2,6-substituted-4-monosubstituted amino-pyrimidine as prostaglandin d2 receptor antagonists

Publications (2)

Publication Number Publication Date
JP2009533473A JP2009533473A (ja) 2009-09-17
JP2009533473A5 true JP2009533473A5 (cg-RX-API-DMAC7.html) 2010-05-27

Family

ID=38294040

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009505615A Abandoned JP2009533473A (ja) 2006-04-12 2007-04-12 プロスタグランジンd2受容体アンタゴニストとしての2,6−置換−4−モノ置換アミノ−ピリミジン

Country Status (25)

Country Link
US (1) US20090036469A1 (cg-RX-API-DMAC7.html)
EP (1) EP2010503A1 (cg-RX-API-DMAC7.html)
JP (1) JP2009533473A (cg-RX-API-DMAC7.html)
KR (1) KR20080108287A (cg-RX-API-DMAC7.html)
CN (1) CN101421252B (cg-RX-API-DMAC7.html)
AR (1) AR060403A1 (cg-RX-API-DMAC7.html)
AU (1) AU2007238052B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0710710A2 (cg-RX-API-DMAC7.html)
CA (1) CA2649083C (cg-RX-API-DMAC7.html)
CR (1) CR10249A (cg-RX-API-DMAC7.html)
DO (1) DOP2007000068A (cg-RX-API-DMAC7.html)
EC (1) ECSP088813A (cg-RX-API-DMAC7.html)
HN (1) HN2008001530A (cg-RX-API-DMAC7.html)
MA (1) MA30409B1 (cg-RX-API-DMAC7.html)
MX (1) MX2008011369A (cg-RX-API-DMAC7.html)
NO (1) NO20084291L (cg-RX-API-DMAC7.html)
NZ (1) NZ571793A (cg-RX-API-DMAC7.html)
PE (1) PE20080186A1 (cg-RX-API-DMAC7.html)
RU (1) RU2431631C2 (cg-RX-API-DMAC7.html)
TN (1) TNSN08339A1 (cg-RX-API-DMAC7.html)
TW (1) TW200815395A (cg-RX-API-DMAC7.html)
UA (1) UA95950C2 (cg-RX-API-DMAC7.html)
UY (1) UY30283A1 (cg-RX-API-DMAC7.html)
WO (1) WO2007121280A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200807380B (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5039594B2 (ja) * 2008-02-08 2012-10-03 株式会社日立ハイテクノロジーズ レビュー装置,検査領域設定支援システム、および、欠陥の画像得方法
AR074776A1 (es) * 2008-12-18 2011-02-09 Sanofi Aventis Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente
CA2793223A1 (en) * 2010-03-16 2011-09-22 Aventis Pharmaceuticals Inc. Substituted pyrimidines as prostaglandin d2 receptor antagonists
MX2012010038A (es) * 2010-03-16 2012-10-01 Aventis Pharma Inc Una pirimidina sustituida como un antagonista del receptor de la prostaglandina d2.
CA2805452C (en) 2010-07-05 2018-07-31 Actelion Pharmaceuticals Ltd 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators
EP2621276B1 (en) * 2010-09-30 2017-12-27 Merck Sharp & Dohme Corp. 2-alkoxy pyrimidine pde10 inhibitors
TW201331179A (zh) 2011-12-21 2013-08-01 Actelion Pharmaceuticals Ltd 雜環衍生物及其作為前列腺素d2受體調節劑之用途
EP2885307A1 (en) 2012-07-05 2015-06-24 Actelion Pharmaceuticals Ltd. 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators
EP2912458B1 (en) 2012-10-24 2018-07-18 NYU Winthrop Hospital Non-invasive biomarker to identify subjects at risk of preterm delivery
CA2930008A1 (en) * 2013-11-08 2015-05-14 Kissei Pharmaceutical Co., Ltd. Carboxymethyl piperidine derivative
MY195016A (en) 2014-08-04 2023-01-03 Nuevolution As Optionally Fused Heterocyclyl-Substituted Derivatives of Pyrimidine Useful for The Treatment of Inflammatory, Metabolic, Oncologic and Autoimmune Diseases
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
EA201992676A1 (ru) 2017-05-18 2020-05-06 Идорсия Фармасьютиклз Лтд Фенильные производные в качестве модуляторов pge2 рецепторов
US11325899B2 (en) 2017-05-18 2022-05-10 Idorsia Pharmaceuticals Ltd Benzofurane and benzothiophene derivatives as PGE2 receptor modulators
KR102612140B1 (ko) 2017-05-18 2023-12-08 이도르시아 파마슈티컬스 리미티드 피리미딘 유도체
AR111808A1 (es) 2017-05-18 2019-08-21 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2
KR20200109293A (ko) 2017-09-13 2020-09-22 프로제너티, 인크. 자간전증 바이오마커 및 관련된 시스템 및 방법
AU2020347662B2 (en) * 2019-09-13 2026-07-09 Meiji Co., Ltd. Solid food and solid milk
WO2021113710A1 (en) 2019-12-04 2021-06-10 Progenity, Inc. Assessment of preeclampsia using assays for free and dissociated placental growth factor
AU2020405446A1 (en) 2019-12-20 2022-05-26 Nuevolution A/S Compounds active towards nuclear receptors
BR112022012205A2 (pt) 2019-12-20 2022-09-13 Nuevolution As Compostos ativos para receptores nucleares
JP7713954B2 (ja) 2020-03-31 2025-07-28 ヌエヴォリューション・アクティーゼルスカブ 核内受容体に対して活性な化合物
CA3174252A1 (en) 2020-03-31 2021-10-07 Nuevolution A/S Compounds active towards nuclear receptors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3644799A1 (de) * 1986-06-04 1987-12-10 Hoechst Ag Neue pyrimidin-derivate, deren herstellung und verwendung
US5047554A (en) * 1989-04-18 1991-09-10 Pfizer Inc. 3-substituted-2-oxindole derivatives
SE0200411D0 (sv) * 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
HN2005000795A (es) * 2004-10-15 2010-08-19 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2
GT200600457A (es) * 2005-10-13 2007-04-27 Aventis Pharma Inc Sal de fosfato dihidrogeno como antagonistas del receptor de prostaglandina d2

Similar Documents

Publication Publication Date Title
RU2008144578A (ru) 2,6-замещенные-4-монозамещенные аминопиримидины как антогонисты рецепторов простагландина d2
JP2009544721A5 (cg-RX-API-DMAC7.html)
JP5085659B2 (ja) L−cpt1阻害剤として有用なインダゾール誘導体
CA2625563A1 (en) Dihydrogen phosphate salt of a prostaglandin d2 receptor antagonist
TNSN07251A1 (en) 2-phenyl-indoles as prostaglandin d2 receptor antagonists
TNSN07098A1 (en) 2,6- substituted -4- monosubstitutedamino-pyrimidine as prostaglandin d2 receptor antagonists
AR062051A1 (es) 2-fenilindoles como antagonistas del receptor de la prostaglandina d₂
JP2013542937A5 (cg-RX-API-DMAC7.html)
NZ566788A (en) Biaryl substituted heterocycle inhibitors of LTA4H for treating inflammation
CN1823063A (zh) 作为磷酸二酯酶抑制剂的喹啉衍生物
CN101970405A (zh) 吲哚及其治疗用途
JP2016540749A5 (cg-RX-API-DMAC7.html)
PE20081889A1 (es) Indol carboxamidas como inhibidores de ikk2
JP2008543860A5 (cg-RX-API-DMAC7.html)
JP2008528606A5 (cg-RX-API-DMAC7.html)
BR0308518A (pt) Compostos ácidos carboxìlicos e drogas contendo os compostos como o ingrediente ativo
JP2011519845A5 (cg-RX-API-DMAC7.html)
JP2012527487A5 (cg-RX-API-DMAC7.html)
NZ595797A (en) 2,5-disubstituted arylsulfonamide ccr3 antagonists
JP2009521431A5 (cg-RX-API-DMAC7.html)
NZ620092A (en) Arylsulfonamide ccr3 agtagonists
RU2012143978A (ru) Замещенный пиримидин в качестве антагониста рецептора простагландина d2
EP1666473A4 (en) CARBOXYLIC ACID COMPOUNDS AND MEDICINAL COMPOSITIONS CONTAINING THE SAME AS ACTIVE INGREDIENT
NZ587153A (en) Pyrimidine-containing compounds for treating inflammation and immunological diseases
WO2004006922A1 (en) Aryl piperidine derivatives as inducers of ldl-receptor expression for the treatment of hypercholesterolemia